Overview

Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
Phase:
Phase 2
Details
Lead Sponsor:
Veloxis Pharmaceuticals
Collaborator:
CTI Clinical Trial and Consulting Services
Treatments:
Tacrolimus